This segment focuses on the development of novel immunotherapies for the treatment of various cancers. Research and development activities include the gp96 platform, which is designed to stimulate and expand T-cells, and the development of products like HS-110 and HS-130, which are in clinical trials for non-small cell lung cancer and advanced solid tumors, respectively. The segment utilizes technologies such as allogenic cell-based platforms (ImPACT) and antigen-driven T-cell activation (ComPACT). The goal is to improve patient outcomes by harnessing the power of the immune system to fight cancer. Market positioning is based on developing first-in-class therapies. Future opportunities include expanding the pipeline to address additional cancer types and exploring combination therapies. Regulatory and clinical aspects involve conducting clinical trials and seeking FDA approval for product candidates. Partnerships and collaborations are essential for advancing research and development, including collaborations with universities and other research institutions.

This segment is dedicated to the development of vaccines to prevent and treat infectious diseases, including a COVID-19 vaccine currently in the preclinical stage. Research and development efforts focus on leveraging the company's gp96 platform to create effective and safe vaccines. The segment utilizes technologies and methodologies related to immune modulation and antigen presentation to stimulate an immune response. The primary therapeutic area is infectious diseases, with the goal of preventing and controlling outbreaks. Patient impact is significant, as successful vaccines can protect individuals and communities from serious illnesses. Market positioning involves developing innovative vaccine candidates. Future opportunities include expanding the vaccine pipeline to address other infectious diseases and exploring partnerships for manufacturing and distribution. Regulatory and clinical aspects involve conducting preclinical studies and clinical trials to demonstrate safety and efficacy. Collaborations with research institutions and biomanufacturing facilities are crucial for vaccine development and production.

This segment focuses on developing therapies that modulate the immune system through T-cell co-stimulation. The primary research and development activity involves PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25, which is currently in Phase I clinical trials. The segment utilizes antibody-based technologies to enhance T-cell activation and immune responses. The therapeutic areas covered include various immunotherapy approaches, with the aim of improving the efficacy of cancer treatments. Patient impact is addressed by providing new treatment options for patients with advanced solid tumors. Market positioning is based on developing innovative immunotherapies. Future opportunities include expanding the application of DR3/TNFRSF25 targeting to other diseases and exploring combination therapies. Regulatory and clinical aspects involve conducting clinical trials and seeking regulatory approvals. Partnerships and collaborations are essential for advancing research and development, including collaborations with research institutions and other biopharmaceutical companies.